Literature DB >> 19497039

Role of non-HLA genetic variants in end-stage renal disease.

P Ranganath1, G Tripathi, R K Sharma, S N Sankhwar, S Agrawal.   

Abstract

Cytokines and intercellular adhesion molecule (ICAM) play a crucial role in the pathogenesis of primary kidney disease and progression to end-stage renal disease (ESRD). Cytokine secretion is reported to be dependent on the single nucleotide polymorphisms located in the cytokine genes. The role of different polymorphisms in cytokines and ICAM genes as probable susceptibility factors for ESRD has been explored in the present study. The study was conducted on 258 ESRD patients and on ethnically matched 569 controls. Individuals were genotyped for interleukin (IL)-6 (G174C), IL-4 (C590T), tumor necrosis factor-alpha (TNF-alpha) (-G308A and -G238A) and ICAM-1 (A469G) gene polymorphisms using standard polymerase chain reaction-restriction fragment length polymorphism-based method. We observed significant difference in the genotype frequencies of the TNF-alpha-308AA [P = 0.001; odds ratios (OR) = 7.61, 95% confidence intervals (CI) = 2.1-27.9] and TNF-alpha-238AA (P = 0.001; OR = 5.8, 95% CI = 2.2-15.1). Furthermore, C allele of IL-6 -G174C and G allele of ICAM-1 A469G were significantly different in ESRD patients when compared with controls (P = 0.0001; OR = 5.5, 95% CI = 3.9-7.7 and P < 0.0001; OR = 3.8, 95% CI = 3.1-4.7). For the IL-4 C590T polymorphism, although the homozygous mutant genotype (TT) was not found to be significantly associated with ESRD, a statistically significant association with T allele (P = 0.008) was observed. Furthermore, combined analysis showed a higher risk in ESRD patients with high IL-4- and low IL-6-producing genotypes, low IL-4- and low IL-6-producing genotypes and high-producing genotype of TNF-alpha (308 and 238) with the increased risk of 6.47-, 3.7- and 3.3-fold, respectively. Our results suggest that IL-6, IL-4, TNF-alpha and ICAM gene polymorphisms are implicated in ESRD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497039     DOI: 10.1111/j.1399-0039.2009.01276.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  7 in total

1.  The Association between Human Leukocyte Antigens and Hypertensive End-Stage Renal Failure among Yemeni Patients.

Authors:  Mogahid Y Nassar; Hassan A Al-Shamahy; Haitham A A Masood
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

Review 2.  Moving beyond HLA: a review of nHLA antibodies in organ transplantation.

Authors:  Tara K Sigdel; Minnie M Sarwal
Journal:  Hum Immunol       Date:  2013-07-19       Impact factor: 2.850

3.  HLA class I and class II associations with ESRD in Saudi Arabian population.

Authors:  Nuha Mahmoud Hamdi; Fadel Hassan Al-Hababi; Amr Ekhlas Eid
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

Review 4.  Unraveling the Role of Allo-Antibodies and Transplant Injury.

Authors:  Yoshiko Matsuda; Minnie M Sarwal
Journal:  Front Immunol       Date:  2016-10-21       Impact factor: 7.561

5.  A meta-analysis on correlation between interleukin-6 -174G/C polymorphism and end-stage renal disease.

Authors:  Ye Feng; Yan Tang; Hongwei Zhou; Kaiqing Xie
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

6.  Genetic Variants Associated with Chronic Kidney Disease in a Spanish Population.

Authors:  Zuray Corredor; Miguel Inácio da Silva Filho; Lara Rodríguez-Ribera; Antonia Velázquez; Alba Hernández; Calogerina Catalano; Kari Hemminki; Elisabeth Coll; Irene Silva; Juan Manuel Diaz; José Ballarin; Martí Vallés Prats; Jordi Calabia Martínez; Asta Försti; Ricard Marcos; Susana Pastor
Journal:  Sci Rep       Date:  2020-01-10       Impact factor: 4.379

7.  Polymorphism of interleukin-6 -174 G/C (rs1800795) & the corresponding interleukin-6 level as a prognostic marker of cervical cancer.

Authors:  Priyanka Wagh; Priyanka Kulkarni; Shilpa Kerkar; Hemant Tongaonkar; Hemangi Chaudhari; Himangi Warke; Kedar Deodhar; Bharat Rekhi; Jayanti Mania-Pramanik
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.